Logiscreen

Aclaris Therapeutics Inc

$5.32
Market Cap 743.01M
ROE -61.6%
Gross Margin 10.8%
Debt/Equity 0.0
Current Ratio 3.5
Revenue QoQ -8.3%
EPS QoQ 0.2%
F-Score 4

About

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation.

Exchange
NASDAQ
Sector
Healthcare
Industry
Diagnostics & Research

Sector context

Healthcare

Undervalued

Trading at a discount to sector peers

P/E
-8.68
vs median 36.93
P/B
4.21
vs median 2.32
ROE
-0.56
vs median 0.09

Lower quality - review fundamentals carefully

Small-cap company with higher volatility

Similar companies

Primary metric
Overlay metric
Loading chart data...
Fetching latest financial metrics